Cbd Life Sciences Inc
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, coffee, wine, skincare line, tablets, and a line of pet products. CBD Life Sciences Inc. formerly known as Optium Cyber Systems, Inc. and… Read more
Cbd Life Sciences Inc (CBDL) - Total Assets
Latest total assets as of March 2025: $516.74K USD
Based on the latest financial reports, Cbd Life Sciences Inc (CBDL) holds total assets worth $516.74K USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cbd Life Sciences Inc - Total Assets Trend (2011–2024)
This chart illustrates how Cbd Life Sciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cbd Life Sciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Cbd Life Sciences Inc's total assets of $516.74K consist of 59.7% current assets and 40.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $31.80K | 7.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.51K | 2.3% |
| Goodwill | $100.00K | 24.6% |
Asset Composition Trend (2011–2024)
This chart illustrates how Cbd Life Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cbd Life Sciences Inc's current assets represent 59.7% of total assets in 2024, an increase from 0.1% in 2011.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, up from 0.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, a decrease from 98.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 24.6% of total assets.
Cbd Life Sciences Inc Competitors by Total Assets
Key competitors of Cbd Life Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Cbd Life Sciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cbd Life Sciences Inc generates 0.27x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cbd Life Sciences Inc is currently not profitable relative to its asset base.
Cbd Life Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.60 | 4.16 | 1.83 |
| Quick Ratio | 4.11 | 3.95 | 1.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $290.64K | $ 140.71K | $ 176.23K |
Cbd Life Sciences Inc - Advanced Valuation Insights
This section examines the relationship between Cbd Life Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.06 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | $406.75K |
| Market Capitalization | $124.07K USD |
Valuation Analysis
Below Book Valuation: The market values Cbd Life Sciences Inc's assets below their book value (0.31 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Cbd Life Sciences Inc's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Cbd Life Sciences Inc (2011–2024)
The table below shows the annual total assets of Cbd Life Sciences Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $406.75K | -3.00% |
| 2023-12-31 | $419.33K | -11.38% |
| 2022-12-31 | $473.16K | -65.29% |
| 2021-12-31 | $1.36 Million | +848.65% |
| 2020-12-31 | $143.72K | -90.36% |
| 2019-12-31 | $1.49 Million | +366.56% |
| 2018-12-31 | $319.70K | -88.00% |
| 2017-12-31 | $2.66 Million | +321.58% |
| 2014-12-31 | $632.08K | -4.65% |
| 2013-12-31 | $662.90K | +53.88% |
| 2012-12-31 | $430.80K | -3.05% |
| 2011-12-31 | $444.35K | -- |